[CONTRIBUTIONS TO THE WATER-ELECTROLYTE BALANCE DURING PREGNANCY. I. SERUM AND URINE ELECTROLYTES DURING THE LAST TRIMESTER OF PREGNANCY].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to L HELLER.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A serological trial of a formolized monovalent Asian influenza vaccine of conventional type, using a range of falling vaccine dilutions, showed a satisfactory antihaemagglutinin response in groups of volunteers vaccinated with relatively low numbers of haemagglutinating units (HU) of the vaccine.Booster injections, given 15-19 days after the primary vaccination, gave a further increase and more persistence of antibody response.In a field protection trial, performed in more than 1000 recruits who received a similar vaccine prepared from another line of the same virus strain, a good degree of protection (57%-78%) was obtained after a single injection of 2000 HU of aqueous vaccine. A lower but still statistically significant degree of protection (29%-45%) obtained with only 400 HU of the vaccine adsorbed on aluminium phosphate. Two injections or 2000 or 400 HU of vaccine (without AlPO(4)), given 9 days apart, protected, respectively, 69%-86% and 45%-51% of the vaccinated. The slightly better protective effect of the two-injection scheme appears to be due to the double amount of vaccine given rather than to a recall reaction.The numerical results of both trials were used for an evaluation of the quantitative relation between the antibody-stimulating and protective effects of influenza vaccines.Some pitfalls in the current method of expressing the potency of influenza vaccines in terms of their haemagglutinin content are discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.